Rising Concerns Over Children's Use of E-cigarettes in Queensland.

Jul.29.2024
Rising Concerns Over Children's Use of E-cigarettes in Queensland.
In Queensland, Australia, children as young as six are being suspended or expelled from school for using e-cigarettes.

According to the latest data from the Queensland Department of Education in Australia, some children as young as six years old have been suspended or expelled from school for using e-cigarettes. In the past 18 months, more than 600 cases of children using e-cigarettes have been reported in primary schools in Queensland.


Meanwhile, a high school in Queensland reported a record of up to 5998 cases of e-cigarette smoking, with over 700 cases coming from students in the seventh grade.


Ramya Raman, Acting Vice President of the Royal Australian College of General Practitioners, stated in an interview with the Courier Mail that smoking could cause "irreversible" damage.


E-cigarettes contain substances that are inherently harmful aerosols, and these chemicals can have a negative impact on learning, behavior development, and attention span.


Starting from July 1st, purchasing e-cigarettes in Australia without a prescription will be considered illegal. However, starting from October, individuals over the age of 18 can purchase e-cigarettes over the counter after discussing the dangers of e-cigarettes with a pharmacist.


We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

FDA Appoints Bret Koplow as Acting Director of CTP
FDA Appoints Bret Koplow as Acting Director of CTP
According to the U.S. Food and Drug Administration’s website, Bret Koplow has been appointed acting director of the Center for Tobacco Products (CTP). Koplow has been with the FDA since 2011, holding several key roles, most recently serving as senior advisor to the FDA Commissioner.
May.21 by 2FIRSTS.ai
FDA Embraces AI: Generative System to Be Fully Operational by June's End
FDA Embraces AI: Generative System to Be Fully Operational by June's End
FDA plans to fully integrate a generative AI system across its centers by June 30, 2025. This follows the successful completion of an initial pilot, marking a shift in the agency's approach to regulatory processes. The AI tools are expected to streamline the drug approval process, which typically takes six to ten months, by reducing time spent on repetitive tasks.
May.09 by 2FIRSTS.ai
Exhibition Observation | HQD and OEM Brand AVOTX Jointly Participate in the Exhibition, Focusing on Customized OEM Business
Exhibition Observation | HQD and OEM Brand AVOTX Jointly Participate in the Exhibition, Focusing on Customized OEM Business
At the 2025 Dubai World Vape Show, HQD and its OEM technology brand AVOTX jointly participated in the exhibition with a unified booth design style. AVOTX showcased a variety of OEM products, including e-cigarettes with transparent oil tanks and metal materials.
Jun.23
Three Sizes, Multiple Pods: Aspire Launches Open-System E-Cigarette Pixo Neo
Three Sizes, Multiple Pods: Aspire Launches Open-System E-Cigarette Pixo Neo
Aspire launches Pixo Neo, an open-system e-cigarette with a 0.85-inch TFT touch screen, compatible with 2.0ml top-fill and 3.0ml side-fill pods. Available on Aspire's website and in Europe for around €19.90.
May.06 by 2FIRSTS.ai
FDA Launches National Priority Review Program: Drugs Aligned with U.S. Priorities May Be Approved in as Little as One Month
FDA Launches National Priority Review Program: Drugs Aligned with U.S. Priorities May Be Approved in as Little as One Month
The FDA has launched the Commissioner’s National Priority Voucher (CNPV) program, reducing the review time for certain drugs to as little as 1–2 months. While the program currently applies only to pharmaceuticals, it demonstrates the FDA’s capacity to reform its review pathways. Whether a similar mechanism could extend to tobacco products now appears to be a matter of timing and technical details.
Jun.18
U.S. Compliance Specialist: Why an STN Falls Short for NGPs Entering the U.S. Market
U.S. Compliance Specialist: Why an STN Falls Short for NGPs Entering the U.S. Market
Many manufacturers misunderstand the role of an STN in the U.S. regulatory framework. This article explains why only a fully approved PMTA ensures legal market access—and why stopping at the STN stage could carry significant risks.
May.09